Literature DB >> 34709473

Natural history of Von Hippel-Lindau disease-associated and sporadic clear cell renal cell carcinoma: a comparative study.

Jie Wang1,2,3, Lei Zhang1,2,3, Jianhui Qiu1,2,3, Kan Gong4,5,6, Xuesong Li7,8,9, Ziao Li1,2,3, Yucai Wu1,2,3, Cuijian Zhang1,2,3, Lin Yao1,2,3, Liqun Zhou1,2,3.   

Abstract

PURPOSE: To compare the tumor growth kinetics between sporadic clear cell renal cell carcinoma (ccRCC) and Von Hippel-Lindau disease-associated renal cell carcinoma (VHL-associated RCC). To analyze predictive markers for the growth rate of these two types of RCC.
METHODS: The clinical data of patients with renal tumors who received active surveillance were collected retrospectively. Immunohistochemical staining was utilized to analyze the expression levels of VHL, PBRM1, H3K36me3, and BAP1 in the postoperative specimens.
RESULTS: The age of the VHL group was significantly younger than that of the sporadic group (P < 0.0001). The mean linear growth rate (LGR) was significantly faster in the sporadic group (P = 0.0004). The tumors of those in the sporadic group tended to have a higher histologic grade (P = 0.0011). In the sporadic group, tumor histologic grade was an independent predictor for rapid mean LGR (P = 0.0022). In the VHL group, initial maximal tumor diameter (MTD) was the only independent predictor for rapid mean LGR (P < 0.0001). Tumors with low VHL expression and negative PBRM1 expression showed a faster growth rate in the sporadic group (P = 0.001 and P = 0.008, respectively). The expression levels of the four biomarkers showed no impact on the tumor growth rate in the VHL group.
CONCLUSION: Sporadic ccRCC grew faster than VHL-associated RCC. High histologic grade, low VHL expression and negative PBRM1 expression were predictors of faster growth in sporadic ccRCC. A large initial MTD was a predictor of faster growth for VHL-associated RCC.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Active surveillance; Clear cell renal cell carcinoma; Growth rate; Natural history; VHL-associated RCC

Mesh:

Substances:

Year:  2021        PMID: 34709473     DOI: 10.1007/s00432-021-03806-0

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.322


  36 in total

1.  Guideline for management of the clinical T1 renal mass.

Authors:  Steven C Campbell; Andrew C Novick; Arie Belldegrun; Michael L Blute; George K Chow; Ithaar H Derweesh; Martha M Faraday; Jihad H Kaouk; Raymond J Leveillee; Surena F Matin; Paul Russo; Robert G Uzzo
Journal:  J Urol       Date:  2009-08-14       Impact factor: 7.450

2.  Outcomes following partial nephrectomy by tumor size.

Authors:  Paul L Crispen; Stephen A Boorjian; Christine M Lohse; Thomas S Sebo; John C Cheville; Michael L Blute; Bradley C Leibovich
Journal:  J Urol       Date:  2008-09-17       Impact factor: 7.450

3.  Rising incidence of renal cell cancer in the United States.

Authors:  W H Chow; S S Devesa; J L Warren; J F Fraumeni
Journal:  JAMA       Date:  1999-05-05       Impact factor: 56.272

Review 4.  The natural history of observed enhancing renal masses: meta-analysis and review of the world literature.

Authors:  Sam N Chawla; Paul L Crispen; Alexandra L Hanlon; Richard E Greenberg; David Y T Chen; Robert G Uzzo
Journal:  J Urol       Date:  2006-02       Impact factor: 7.450

5.  Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance.

Authors:  Paul L Crispen; Rosalia Viterbo; Stephen A Boorjian; Richard E Greenberg; David Y T Chen; Robert G Uzzo
Journal:  Cancer       Date:  2009-07-01       Impact factor: 6.860

6.  Decreasing size at diagnosis of stage 1 renal cell carcinoma: analysis from the National Cancer Data Base, 1993 to 2004.

Authors:  Matthew R Cooperberg; Katherine Mallin; Jamie Ritchey; Jacqueline D Villalta; Peter R Carroll; Christopher J Kane
Journal:  J Urol       Date:  2008-06       Impact factor: 7.450

7.  Contemporary epidemiology of renal cell cancer.

Authors:  Wong-Ho Chow; Susan S Devesa
Journal:  Cancer J       Date:  2008 Sep-Oct       Impact factor: 3.360

8.  Predicting growth of solid renal masses under active surveillance.

Authors:  Paul L Crispen; Yu-Ning Wong; Richard E Greenberg; David Y T Chen; Robert G Uzzo
Journal:  Urol Oncol       Date:  2008 Sep-Oct       Impact factor: 3.498

9.  Dynamic histone H3 methylation during gene induction: HYPB/Setd2 mediates all H3K36 trimethylation.

Authors:  John W Edmunds; Louis C Mahadevan; Alison L Clayton
Journal:  EMBO J       Date:  2007-12-20       Impact factor: 11.598

10.  Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma.

Authors:  Svenja Bihr; Riuko Ohashi; Ariane L Moore; Jan H Rüschoff; Christian Beisel; Thomas Hermanns; Axel Mischo; Claudia Corrò; Jörg Beyer; Niko Beerenwinkel; Holger Moch; Peter Schraml
Journal:  Neoplasia       Date:  2019-01-16       Impact factor: 5.715

View more
  1 in total

1.  Comprehensive analysis of 7-methylguanosine and immune microenvironment characteristics in clear cell renal cell carcinomas.

Authors:  Yu Xiao; Junfeng Yang; Maolin Yang; Jinjun Len; Yanhong Yu
Journal:  Front Genet       Date:  2022-08-08       Impact factor: 4.772

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.